Targeting glutamate metabolism in chronic lung diseases

Abstract

Amino acids are necessary for all life forms, which play various roles. Disorder of amino acid metabolism is now considered an important driving mechanism in diverse pulmonary conditions, particularly chronic lung diseases like chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis and lung cancer. Glutamate actively participates in multiple vital biological processes, while the intricate glutamate metabolism, glutamate receptors and glutamate transporters assume crucial regulatory functions in the development of chronic lung diseases. This review aims to discuss the relationship between glutamate dysfunction and chronic lung diseases. By discussing the physiological and pathological function of glutamate, we probe the potential drug targets for chronic lung diseases in the glutamate pathway.

Keywords

amino acid / chronic lung diseases / glutamate / glutamate transports / metabolism dysfunction

References

[1] GBD Chronic Respiratory Disease Collaborators. Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Respir Med. 2020;8(6):585-596.

[2] KeirHR, Chalmers JD. Neutrophil extracellular traps in chronic lung disease: implications for pathogenesis and therapy. Eur Respir Rev. 2022;31(163):210241.

[3] DeBerardinisRJ, Thompson CB. Cellular metabolism and disease: what do metabolic outliers teach us? Cell. 2012;148(6):1132-1144.

[4] WangL, ChenX, LiX, et al. Developing a novel strategy for COPD therapy by targeting Nrf2 and metabolism reprogramming simultaneously. Free Radic Biol Med. 2021;169:436-445.

[5] YangC, WangG, ZhanW, et al. The identification of metabolism-related subtypes and potential treatments for idiopathic pulmonary fibrosis. Front Pharmacol. 2023;14:1173961.

[6] JiangT, DaiL, LiP, et al. Lipid metabolism and identification of biomarkers in asthma by lipidomic analysis. Biochim Biophys Acta Mol Cell Biol Lipids. 2021;1866(2):158853.

[7] NambiarS, Bong How S, GummerJ, et al. Metabolomics in chronic lung diseases. Respirology. 2020;25(2):139-148.

[8] WeiB, TianT, LiuY, et al. The diagnostic value of homocysteine for the occurrence and acute progression of chronic obstructive pulmonary disease. BMC Pulm Med. 2020;20(1):237.

[9] InoueS, IkedaH. Differences in plasma amino acid levels in patients with and without bacterial infection during the early stage of acute exacerbation of COPD. Int J Chronic Obstruct Pulm Dis. 2019;14:575-583.

[10] ArshadH, SiokisA, FrankeR, et al. Reprogramming of amino acid metabolism differs between community-acquired pneumonia and infection-associated exacerbation of chronic obstructive pulmonary disease. Cells. 2022;11(15):2283.

[11] GauggMT, EnglerA, BregyL, et al. Molecular breath analysis supports altered amino acid metabolism in idiopathic pulmonary fibrosis. Respirology. 2019;24(5):437-444.

[12] ShenQ, YuH, LiuY, et al. Combined exposure of MAHs and PAHs enhanced amino acid and lipid metabolism disruption in epithelium leading asthma risk. Environ Pollut. 2024;343:123261.

[13] Garcia-GaytanAC, Hernandez-Abrego A, Diaz-MunozM, et al. Glutamatergic system components as potential biomarkers and therapeutic targets in cancer in non-neural organs. Front Endocrinol. 2022;13:1029210.

[14] MatousekWM, CianiB, FitchCA, et al. Electrostatic contributions to the stability of the GCN4 leucine zipper structure. J Mol Biol. 2007;374(1):206-219.

[15] BrosnanJT, Brosnan ME. Glutamate: a truly functional amino acid. Amino Acids. 2013;45(3):413-418.

[16] DayeD, WellenKE. Metabolic reprogramming in cancer: unraveling the role of glutamine in tumorigenesis. Semin Cell Dev Biol. 2012;23(4):362-369.

[17] DeBerardinisRJ, Mancuso A, DaikhinE, et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci USA. 2007;104(49):19345-19350.

[18] HansenKB, Wollmuth LP, BowieD, et al. Structure, function, and pharmacology of glutamate receptor ion channels. Pharmacol Rev. 2021;73(4):298-487.

[19] LauA, Tymianski M. Glutamate receptors, neurotoxicity and neurodegeneration. Pflug Arch. 2010;460(2):525-542.

[20] MangiaS, GioveF, DinuzzoM. Metabolic pathways and activity-dependent modulation of glutamate concentration in the human brain. Neurochem Res. 2012;37(11):2554-2561.

[21] DuJ, LiXH, ZhangW, et al. Involvement of glutamate-cystine/glutamate transporter system in aspirin-induced acute gastric mucosa injury. Biochem Biophys Res Commun. 2014;450(1):135-141.

[22] Maltais-PayetteI, Boulet MM, PrehnC, et al. Circulating glutamate concentration as a biomarker of visceral obesity and associated metabolic alterations. Nutr Metab. 2018;15:78.

[23] OttossonF, SmithE, MelanderO, et al. Altered asparagine and glutamate homeostasis precede coronary artery disease and type 2 diabetes. J Clin Endocrinol Metab. 2018;103(8):3060-3069.

[24] LiuY, TangA, LiuM, et al. Tuberostemonine may enhance the function of the SLC7A11/glutamate antiporter to restrain the ferroptosis to alleviate pulmonary fibrosis. J Ethnopharmacol. 2024;318(Pt B):116983.

[25] RoqueW, RomeroF. Cellular metabolomics of pulmonary fibrosis, from amino acids to lipids. Am J Physiol Cell Physiol. 2021;320(5):C689-C695.

[26] FahrmannJF, Vykoukal JV, OstrinEJ. Amino acid oncometabolism and immunomodulation of the tumor microenvironment in lung cancer. Front Oncol. 2020;10:276.

[27] DuJ, LiXH, LiYJ. Glutamate in peripheral organs: biology and pharmacology. Eur J Pharmacol. 2016;784:42-48.

[28] CamachoA, Massieu L. Role of glutamate transporters in the clearance and release of glutamate during ischemia and its relation to neuronal death. Arch Med Res. 2006;37(1):11-18.

[29] WilliamsLE, Featherstone DE. Regulation of hippocampal synaptic strength by glial xCT. J Neurosci. 2014;34(48):16093-16102.

[30] RobertSM, Sontheimer H. Glutamate transporters in the biology of malignant gliomas. Cell Mol Life Sci. 2014;71(10):1839-1854.

[31] RobertSM, Ogunrinu-Babarinde T, HoltKT, et al. Role of glutamate transporters in redox homeostasis of the brain. Neurochem Int. 2014;73:181-191.

[32] LewerenzJ, MaherP, MethnerA. Regulation of xCT expression and system x (c) (-) function in neuronal cells. Amino Acids. 2012;42(1):171-179.

[33] WyllieDJA, BowieD. Ionotropic glutamate receptors: structure, function and dysfunction. J Physiol. 2022;600(2):175-179.

[34] ChenTS, HuangTH, LaiMC, et al. The role of glutamate receptors in epilepsy. Biomedicines. 2023;11(3):783.

[35] KodaS, HuJ, JuX, et al. The role of glutamate receptors in the regulation of the tumor microenvironment. Front Immunol. 2023;14:1123841.

[36] ShenZ, XiangM, ChenC, et al. Glutamate excitotoxicity: potential therapeutic target for ischemic stroke. Biomed Pharmacother. 2022;151:113125.

[37] UnoY, CoyleJT. Glutamate hypothesis in schizophrenia. Psychiatry Clin Neurosci. 2019;73(5):204-215.

[38] MurroughJW, Abdallah CG, MathewSJ. Targeting glutamate signalling in depression: progress and prospects. Nat Rev Drug Discov. 2017;16(7):472-486.

[39] BlackerCJ, LewisCP, FryeMA, et al. Metabotropic glutamate receptors as emerging research targets in bipolar disorder. Psychiatry Res. 2017;257:327-337.

[40] PeregoC, Di Cairano ES, GalliA, et al. Autoantibodies against the glial glutamate transporter GLT1/EAAT2 in type 1 diabetes mellitus – clues to novel immunological and non-immunological therapies. Pharmacol Res. 2022;177:106130.

[41] HermanussenM, GarciaAP, SunderM, et al. Obesity, voracity, and short stature: the impact of glutamate on the regulation of appetite. Eur J Clin Nutr. 2006;60(1):25-31.

[42] ZhaoJV, KwokMK, SchoolingCM. Effect of glutamate and aspartate on ischemic heart disease, blood pressure, and diabetes: a Mendelian randomization study. Am J Clin Nutr. 2019;109(4):1197-1206.

[43] SloskyLM, BassiriRad NM, SymonsAM, et al. The cystine/glutamate antiporter system xc-drives breast tumor cell glutamate release and cancer-induced bone pain. Pain. 2016;157(11):2605-2616.

[44] da CunhaAA, PauliV, SaciuraVC, et al. N-methyl-D-aspartate glutamate receptor blockade attenuates lung injury associated with experimental sepsis. Chest. 2010;137(2):297-302.

[45] De BundelD, Schallier A, LoyensE, et al. Loss of system x(c)-does not induce oxidative stress but decreases extracellular glutamate in hippocampus and influences spatial working memory and limbic seizure susceptibility. J Neurosci. 2011;31(15):5792-5803.

[46] WangM, LuoZ, LiuS, et al. Glutamate mediates hyperoxia-induced newborn rat lung injury through N-methyl-D-aspartate receptors. Am J Respir Cell Mol Biol. 2009;40(3):260-267.

[47] MaL, LiuW, FengD, et al. Protective effect of NMDA receptor antagonist memantine on acute lung injury in mice. Zhong nan da xue xue bao Yi xue ban = J Central South Univ Med Sci. 2014;39(1):12-16.

[48] TangF, YueS, LuoZ, et al. Role of N-methyl-D-aspartate receptor in hyperoxia-induced lung injury. Pediatr Pulmonol. 2005;40(5):437-444.

[49] LiY, LiuY, PengX, et al. NMDA receptor antagonist attenuates bleomycin-induced acute lung injury. PLoS One. 2015;10(5):e0125873.

[50] Ben-AbrahamR, Guttman M, FlaishonR, et al. Mesenteric artery clamping/unclamping-induced acute lung injury is attenuated by N-methyl-D-aspartate antagonist dextromethorphan. Lung. 2006;184(6):309-317.

[51] YamanMO, SonmezOF, Ekiz-YilmazT, et al. The role of NMDA glutamate receptors in lung injury caused by chronic long-term intermittent hypobaric hypoxia. Braz J Med Biol Res = Rev bras pesquisas med biol. 2023;56:e12549.

[52] ShangLH, LuoZQ, DengXD, et al. Expression of N-methyl-D-aspartate receptor and its effect on nitric oxide production of rat alveolar macrophages. Nitric Oxide: Biol Chem. 2010;23(4):327-331.

[53] LiW, QiuX, WangJ, et al. The therapeutic efficacy of glutamine for rats with smoking inhalation injury. Int Immunopharmacol. 2013;16(2):248-253.

[54] VulimiriSV, MisraM, HammJT, et al. Effects of mainstream cigarette smoke on the global metabolome of human lung epithelial cells. Chem Res Toxicol. 2009;22(3):492-503.

[55] HaakAJ, Ducharme MT, Diaz EspinosaAM, et al. Targeting GPCR signaling for idiopathic pulmonary fibrosis therapies. Trends Pharmacol Sci. 2020;41(3):172-182.

[56] IyinikkelJ, MurrayF. GPCRs in pulmonary arterial hypertension: tipping the balance. Br J Pharmacol. 2018;175(15):3063-3079.

[57] SommerN, Ghofrani HA, PakO, et al. Current and future treatments of pulmonary arterial hypertension. Br J Pharmacol. 2021;178(1):6-30.

[58] WrightDB, Tripathi S, SikarwarA, et al. Regulation of GPCR-mediated smooth muscle contraction: implications for asthma and pulmonary hypertension. Pulm Pharmacol Ther. 2013;26(1):121-131.

[59] ViswanathanG, Mamazhakypov A, SchermulyRT, et al. The role of G protein-coupled receptors in the right ventricle in pulmonary hypertension. Front Cardiovasc Med. 2018;5:179.

[60] LeeA, Anderson AR, StevensM, et al. Excitatory amino acid transporter 5 is widely expressed in peripheral tissues. Eur J Histochem: EJH. 2013;57(1):e11.

[61] KoppulaP, ZhuangL, GanB. Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy. Protein Cell. 2021;12(8):599-620.

[62] MiaoM, PanM, ChenX, et al. IL-13 facilitates ferroptotic death in asthmatic epithelial cells via SOCS1-mediated ubiquitinated degradation of SLC7A11. Redox Biol. 2024;71:103100.

[63] RitzenthalerJD, Torres-Gonzalez E, ZhengY, et al. The profibrotic and senescence phenotype of old lung fibroblasts is reversed or ameliorated by genetic and pharmacological manipulation of Slc7a11 expression. Am J Physiol Lung Cell Mol Physiol. 2022;322(3):L449-L461.

[64] MaedaJ, Higashiyama M, ImaizumiA, et al. Possibility of multivariate function composed of plasma amino acid profiles as a novel screening index for non-small cell lung cancer: a case control study. BMC Cancer. 2010;10:690.

[65] ZhaoQ, CaoY, WangY, et al. Plasma and tissue free amino acid profiles and their concentration correlation in patients with lung cancer. Asia Pac J Clin Nutr. 2014;23(3):429-436.

[66] JanssonLC, Akerman KE. The role of glutamate and its receptors in the proliferation, migration, differentiation and survival of neural progenitor cells. J Neural Transm. 2014;121(8):819-836.

[67] WangZ, WuX, ChenHN, et al. Amino acid metabolic reprogramming in tumor metastatic colonization. Front Oncol. 2023;13:1123192.

[68] GuoW, LiK, SunB, et al. Dysregulated glutamate transporter SLC1A1 propels cystine uptake via Xc(-) for glutathione synthesis in lung cancer. Cancer Res. 2021;81(3):552-566.

[69] AltmanBJ, StineZE, DangCV. From Krebs to clinic: glutamine metabolism to cancer therapy. Nat Rev Cancer. 2016;16(10):619-634.

[70] MomcilovicM, BaileyST, LeeJT, et al. The GSK3 signaling axis regulates adaptive glutamine metabolism in lung squamous cell carcinoma. Cancer Cell. 2018;33(5):905-921 e5.

[71] GuanJ, LoM, DockeryP, et al. The xc-cystine/glutamate antiporter as a potential therapeutic target for small-cell lung cancer: use of sulfasalazine. Cancer Chemother Pharmacol. 2009;64(3):463-472.

[72] RuiuR, CossuC, IacovielloA, et al. Cystine/glutamate antiporter xCT deficiency reduces metastasis without impairing immune system function in breast cancer mouse models. J Exp Clin Cancer Res. 2023;42(1):254.

[73] YangY, HeP, HouY, et al. Osmundacetone modulates mitochondrial metabolism in non-small cell lung cancer cells by hijacking the glutamine/glutamate/alpha-KG metabolic axis. Phytomedicine. 2022;100:154075.

RIGHTS & PERMISSIONS

2024 The Authors. Clinical and Translational Discovery published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.